Client success story
Research Data Strategy for Cell and Gene Therapy
Business Value: Optimizing Research Platforms for Strategic Growth
Summary: Digital Strategy for Chemistry and CGT Transformation
bPrescient worked with a mid-size pharmaceutical company to develop a digital strategy for transforming their chemistry and cell and gene therapy (CGT) platforms to meet the needs of future growth.
Challenge: Fragmented Systems Risk Cost and Schedule Overruns
The company was growing quickly amid a digital transformation from a fragmented and home-grown technology infrastructure into an organized and robust enterprise architecture. The transformation had to align with an approved timeline and budget, so the work had to be organized and efficient. Performing the transformation in an ad-hoc way would lead to cost and schedule overruns and limit the effectiveness of the platforms.
Solution: bPrescient Experts Deliver Comprehensive Transformation Roadmap
bPrescient engaged with the customer and their vendors to deliver the following:
- Reference current and future state architectures, including choices for compound registration and inventory to support Chemistry and CGT functions
- Assessment of integration points between future state architecture and other existing systems
- ROI analysis including licensing, build, sustainability, and time
- Gap analysis and plans to address inconsistencies through additional systems or tools
Outcome: Streamlined Platforms and Confident Implementation
The customer performed their planned digital transformation with clear information on timeline and budget, and ROI of the finished product. This allowed them to align their research objectives with the digital transformation and ensure budget and resource allocation met their research needs.
Let’s talk
Tell us about your toughest R&D challenge and let’s discuss how bPrescient can solve it.
